22041-21-0

Basic information

• Product Name: METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE
• Synonyms: METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE;1-pyrrolidinepropanoicacid,methylester;1-pyrrolidinepropionicacid,methylester;3-(pyrrolidin-1-yl)-propionicacimethylester;methyl1-pyrrolidinepropionate;methyl3-(pyrrolidin-1-yl)propionate;Methyl 3-pyrrolidinopropionate;3-Pyrrolizinopropanoic acid methyl ester
• CAS NO: 22041-21-0
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Mol File: 22041-21-0.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 219.2°Cat760mmHg
• Flash Point: 83.7°C
• Appearance: /
• Density: 1.021g/cm³
• Vapor Pressure: 0.121mmHg at 25°C
• Refractive Index: 1.463
• CAS DataBase Reference: METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE(22041-21-0)
• EPA Substance Registry System: METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE(22041-21-0)

Safety Data

• Hazardous Substances Data: 22041-21-0(Hazardous Substances Data)

Usage

General Description

METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE is a chemical compound with the molecular formula C9H15NO2. It is an ester, often used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and pharmaceutical products. METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE has a pyrrolidine ring, a five-membered nitrogen-containing ring structure, which gives it unique properties and potential applications in drug development. METHYL 3-(PYRROLIDIN-1-YL)PROPANOATE may also be used in research and industrial processes for its potential biological and chemical properties.

InChI:InChI=1/C8H15NO2/c1-11-8(10)4-7-9-5-2-3-6-9/h2-7H2,1H3

Upstream product

• 123-75-1 pyrrolidine 
• 292638-85-8 acrylic acid methyl ester 
• 124-41-4 sodium methylate 
• 23499-08-3 1,3-dimethyl-4-pyrrolidin-1-yl-1,2,3,6-tetrahydro-pyridine 

Downstream Products

• 76234-38-3 β-(1-Pyrrolidinyl)-Propionic Acid 
• 164917-35-5 4-(3'-pyrrolidin-1''-ylpropoxy)benzaldehyde 
• 19748-66-4 3-pyrrolidin-1-yl-propan-1-ol 
• 117123-98-5 N²-butyl-N²-phenyl-6-(2-pyrrolidino-ethyl)-[1,3,5]triazine-2,4-diyldiamine 
• 2344-10-7 perfluoro-N-ethylpyrrolidine 
• 355-25-9 perfluorobutane 
• 124008-13-5 2,2,3,3-tetrafluoro-3-(perfluoropyrrolidin-1-yl)propanoyl fluoride 
• 78159-15-6 1-pentafluoroethyl-octafluoropyrrolidine 
• 59737-32-5 3-(pyrrolidin-1-yl)propanehydrazide 

Relevant articles and documents

Zirconium(IV) chloride-mediated chemoselective conjugate addition of aliphatic amines to α,β-ethylenic compounds

Zirconium chloride efficiently catalyzes the conjugate addition of a variety of aliphatic amines to α,β-unsaturated ester, nitriles, and ketones to give the corresponding β-amino derivatives in excellent yields under mild reaction conditions. Aromatic amines do not participate in this transformation. Copyright Taylor & Francis Group, LLC.

Heterogeneous Aza-Michael Addition Reaction by the Copper-Based Metal–Organic Framework (CuBTC)

Abstract: The copper benzene-1, 3, 5-tricarboxylate metal–organic framework (CuBTC) was found to be an effective heterogeneous catalyst for the aza-Michael addition reaction of the four types of amines to electron deficient alkenes at room temperature. The catalytic protocol showed high product yields and outstanding chemo selectivity. The cyclic amines (piperidine and pyrrolidine) and aliphatic amines (n-dibutylamine) provided aza-Michael addition with a high yield of product (?98%) within shorter reaction period (2?h) at room temperature under mild reaction conditions using CuBTC. However, it was observed that the aza-Michael reaction proceeded more slowly, giving 62% yield of product after 24?h in the case of aromatic amine (aniline) with n-butyl acrylate in the presence of CuBTC under identical reaction conditions. The catalyst could be reused four recycles without losing its initial catalytic activity and selectivity. XRD and SEM analysis further confirmed that the crystallinity of catalyst was retained during the reaction. A reaction mechanism is proposed for the aza-Michael addition reaction over heterogeneous CuBTC catalyst. Graphic Abstract: [Figure not available: see fulltext.].

COMPOUNDS USEFUL IN HIV THERAPY

The invention relates to compounds of Formulas (I), (II) and (III) salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects.

NAPHTHYLUREA DERIVATIVES AND MEDICAL APPLICATIONS THEREOF

The present invention relates to naphthylurea derivatives. Such substances can significantly inhibit VEGFR2 and PDGFR-β receptor tyrosine kinase phosphorylation at nanomolar concentration levels. It is a novel type of tyrosine kinase inhibitors which can be used in the treatment of tyrosine kinase-mediated diseases or symptoms such as malignancies and ocular diseases accompanied with pathologic neovascularization